Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Erika Richtig, Joanna Mangana, Christian Posch, Christoph Hoeller, Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Julian Kofler, Christine Hafner
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ea3dbbcfc7aa40dd9cf2d630e1cec0b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea3dbbcfc7aa40dd9cf2d630e1cec0b6
record_format	dspace
spelling	oai:doaj.org-article:ea3dbbcfc7aa40dd9cf2d630e1cec0b62021-11-16T06:30:05ZReal-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany10.1136/jitc-2020-0017012051-1426https://doaj.org/article/ea3dbbcfc7aa40dd9cf2d630e1cec0b62021-02-01T00:00:00Zhttps://jitc.bmj.com/content/9/2/e001701.fullhttps://doaj.org/toc/2051-1426Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and demonstrated an overall response rate (ORR) of 40.5% and a complete response (CR) rate of 16.6%.Objectives The aim of this study was to assess the outcome of melanoma patients treated with T-VEC in a real-life clinical setting.Methods Based on data from 10 melanoma centers in Austria, Switzerland and southern Germany, we conducted a retrospective chart review, which included 88 patients (44 male, 44 female) with a median age of 72 years (range 36–95 years) treated with T-VEC during the period from May 2016 to January 2020.Results 88 patients fulfilled the inclusion criteria for analysis. The ORR was 63.7%. 38 patients (43.2%) showed a CR, 18 (20.5%) had a partial response, 8 (9.1%) had stable disease and 24 (27.3%) patients had a progressive disease. The median treatment period was 19 weeks (range: 1–65), an average of 11 doses (range: 1–36) were applied. 39 (45.3%) patients developed adverse events, mostly mild, grade I (64.1%).Conclusion This real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs.Erika RichtigJoanna ManganaChristian PoschChristoph HoellerJulia Maria ResslerMatthias KarasekLukas KochRita SilmbrodVeronica Aedo-LopezHelmut KehrerFelix WeihsengruberPeter KoelblingerJulian KoflerChristine HafnerBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Erika Richtig Joanna Mangana Christian Posch Christoph Hoeller Julia Maria Ressler Matthias Karasek Lukas Koch Rita Silmbrod Veronica Aedo-Lopez Helmut Kehrer Felix Weihsengruber Peter Koelblinger Julian Kofler Christine Hafner Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
description	Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and demonstrated an overall response rate (ORR) of 40.5% and a complete response (CR) rate of 16.6%.Objectives The aim of this study was to assess the outcome of melanoma patients treated with T-VEC in a real-life clinical setting.Methods Based on data from 10 melanoma centers in Austria, Switzerland and southern Germany, we conducted a retrospective chart review, which included 88 patients (44 male, 44 female) with a median age of 72 years (range 36–95 years) treated with T-VEC during the period from May 2016 to January 2020.Results 88 patients fulfilled the inclusion criteria for analysis. The ORR was 63.7%. 38 patients (43.2%) showed a CR, 18 (20.5%) had a partial response, 8 (9.1%) had stable disease and 24 (27.3%) patients had a progressive disease. The median treatment period was 19 weeks (range: 1–65), an average of 11 doses (range: 1–36) were applied. 39 (45.3%) patients developed adverse events, mostly mild, grade I (64.1%).Conclusion This real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs.
format	article
author	Erika Richtig Joanna Mangana Christian Posch Christoph Hoeller Julia Maria Ressler Matthias Karasek Lukas Koch Rita Silmbrod Veronica Aedo-Lopez Helmut Kehrer Felix Weihsengruber Peter Koelblinger Julian Kofler Christine Hafner
author_facet	Erika Richtig Joanna Mangana Christian Posch Christoph Hoeller Julia Maria Ressler Matthias Karasek Lukas Koch Rita Silmbrod Veronica Aedo-Lopez Helmut Kehrer Felix Weihsengruber Peter Koelblinger Julian Kofler Christine Hafner
author_sort	Erika Richtig
title	Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
title_short	Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
title_full	Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
title_fullStr	Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
title_full_unstemmed	Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
title_sort	real-life use of talimogene laherparepvec (t-vec) in melanoma patients in centers in austria, switzerland and germany
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/ea3dbbcfc7aa40dd9cf2d630e1cec0b6
work_keys_str_mv	AT erikarichtig reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT joannamangana reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT christianposch reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT christophhoeller reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT juliamariaressler reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT matthiaskarasek reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT lukaskoch reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT ritasilmbrod reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT veronicaaedolopez reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT helmutkehrer reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT felixweihsengruber reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT peterkoelblinger reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT juliankofler reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany AT christinehafner reallifeuseoftalimogenelaherparepvectvecinmelanomapatientsincentersinaustriaswitzerlandandgermany
_version_	1718426699756994560

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Ejemplares similares